Suntrust Banks Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 117,807 shares of the medical research company’s stock after buying an additional 13,150 shares during the quarter. Suntrust Banks Inc.’s holdings in Thermo Fisher Scientific were worth $24,321,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. Icon Wealth Partners LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $105,000. Virtue Capital Management LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $127,000. Johnson Financial Group Inc. grew its holdings in Thermo Fisher Scientific by 2,608.7% in the first quarter. Johnson Financial Group Inc. now owns 623 shares of the medical research company’s stock worth $129,000 after purchasing an additional 600 shares during the last quarter. Premia Global Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $131,000. Finally, Private Capital Group LLC grew its holdings in Thermo Fisher Scientific by 57.3% in the first quarter. Private Capital Group LLC now owns 865 shares of the medical research company’s stock worth $179,000 after purchasing an additional 315 shares during the last quarter. 85.77% of the stock is currently owned by institutional investors.
TMO has been the topic of several analyst reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a report on Monday, April 30th. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the stock an “overweight” rating in a report on Thursday, April 26th. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $224.38.
In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $217.71, for a total transaction of $10,885,500.00. Following the completion of the transaction, the chief executive officer now directly owns 272,122 shares in the company, valued at $59,243,680.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 45,000 shares of the business’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $214.80, for a total transaction of $9,666,000.00. Following the transaction, the chief executive officer now owns 315,122 shares of the company’s stock, valued at $67,688,205.60. The disclosure for this sale can be found here. Insiders have sold 97,706 shares of company stock valued at $21,125,673 over the last 90 days. 0.49% of the stock is currently owned by insiders.
Shares of TMO opened at $206.54 on Friday. The firm has a market cap of $84.01 billion, a PE ratio of 21.76, a P/E/G ratio of 1.53 and a beta of 1.11. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.36. Thermo Fisher Scientific Inc. has a 1-year low of $170.07 and a 1-year high of $226.44.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.08. The firm had revenue of $5.85 billion for the quarter, compared to analyst estimates of $5.62 billion. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.08 earnings per share. sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 10.9 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, July 16th. Investors of record on Friday, June 15th will be given a dividend of $0.17 per share. The ex-dividend date is Thursday, June 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.